Atovaquone and proguanil for Plasmodium falciparum malaria

Lancet

Volumn 347, Issue 9014, 1996, Pages 1511-1514

  Radioff, Paul D ^a   Philipps, Jörg ^a   Nkeyi, Marcel ^a   Hutchinson, David ^c   Kremsner, Peter G ^b,c  

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ATOVAQUONE; PROGUANIL;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; GABON; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTIDRUG RESISTANCE; MUSCLE WEAKNESS; NAUSEA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOMITING;

EID: 0030013581     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90671-6     Document Type: Article

References (29)

1. World Health Organization. World Malaria situation in 1992. Weekly Epidemiol Rec 1994; 69: 309-32.
2. White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 1992; 30: 571-85.
3. Panisco DM, Keystone JS. Treatment of malaria - 1990. Drugs 1990; 39: 160-89.
4. Björkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg 1990; 84: 177-80.
5. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodiaquine induced agranulocytosis and liver damage. BMJ 1986; 292: 721-23.
6. Hatton CSR, Bunch C, Peto TEA, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; i: 411-14.
7. Kremsner PG, Radloff PD, Metzger W, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother 1995; 39: 1603-05.
8. Metzger W, Mordmüller B, Graninger W, Bienzle U, Kremsner PG. High efficacy of short term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrob Agents Chemother 1995; 39: 245-46.
9. Reacher M, Campbell CC, Freeman J, Doberstyn EB, Brandling-Bennett AD. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980. Lancet 1981; ii: 1066-69.
10. Brasseur P, Bitsindou P, Moyou RS, et al. Fast emergence of Plasmodium falciparum resistance to halofantrine. Lancet 1993; 341: 901-02.
11. Brasseur P, Kouamouo J, Moyou-Somo R, Druihle P. Multi-drug resistant falciparum malaria in Cameroon in 1987-88. II. Mefloquine resistance confirmed in vivo and in vitro and its correlation with quinine resistance. Am J Trop Med Hyg 1992; 46: 8-14.
12. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine/sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451-58.
13. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-56.
14. World Health Organization. Review of central nervous system adverse events related to the antimalarial drug, mefloquine (1985-1990), WHO/MAL 911063, Geneva, 1991.
15. Fawaz G, Haddad FS. The effect of lapinone (M-2350) on P vivax infection in man. Am J Trop Med 1951; 31: 569-71.
16. Hammond DJ, Burchell JR, Pudney M. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-lutylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol 1085; 14: 97-109.
17. Hughes WT, Kennedy W, Shenep JL, et al. Safety and pharmacokinetics of 566c80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV) infected men. J Infect Dis 1991; 163: 843-48.
18. Hudson AT, Randall AW, Ginger CD, et al. Novel anti-malarial hydroxynaphthoquinone with potent broad spectrum anti-protozoal activity. Parasitology 1985; 90: 45-55.
19. Hudson AT, Dickins M, Ginger CD, et al. 566C80: a potent broad spectrum antiinfective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991; 17: 427-35.
20. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CG. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg (in press).
21. Fairley NH. Researches on paludrine (M4888) in malaria. Trans R Soc Trop Med Hyg 1946; 40: 105-62.
22. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80: 373-81.
23. Blanchard TJ, Mabey DCW, Hunt-Cooke A, et al. Multiresistant falciparum malaria cured using atovaquone and proguanil. Trans R Soc Trop Med Hyg 1994; 88: 693.
24. Kremsner PG, Winkler S, Brandts C, Graninger W, Bienzle U. Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg 1993; 49: 650-54.
25. Wernsdorfer WH, Payne D. The dynamics of drug-resistance in Plasmodium falciparum. Pharmacol Ther 1991; 50: 95-121.
26. Wildling E, Winkler S, Kremsner PG, Brandts C, Jenne L, Wernsdorfer WH. Malaria epidemiology in the province of Moyen Ogooué, Gabon. Trop Med Parasitol 1995; 46: 77-82.
27. Carme B, Sathounkasi C, Mbitsi A, et al. Efficacité comparée de la chloroquine et de l'amodiaquine (25 et 35 mg/kg) chez des écoliers porteurs de P falciparum (Brazzaville, Mars 1990). Bull Soc Pathol Ex 1991; 84: 77-79.
28. Winkler S, Brandts C, Wernsdorfer WH, Graninger W, Bienzle U, Kremsner PG. Drug sensitivity of Plasmodium falciparum in Gabon. Activity correlations between various antimalarials. Trop Med Parasitol 1994; 45: 214-18.
29. Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis 1994; 169: 467-70.